20 March 2026
Geneva, Friday 20 March 2026 — The Medicines Patent Pool (MPP) today is proud to present its refreshed visual identity designed to better reflect the evolution of its mission, scope and role in expanding equitable access to innovative medicines and other health technologies for people in low- and middle-income countries.
Since its creation by Unitaid in 2010, MPP has worked to expand access to innovative medicines through public health-oriented voluntary licensing. Over time, its mandate has expanded, from HIV to other infectious and non-communicable diseases, in line with the changing global health landscape. Today, MPP supports access not only to medicines, but also to a broader range of health products and technologies – including long-acting technologies, vaccines and medical devices – and increasingly supports technology transfer to help strengthen sustainable manufacturing and supply.
“Our mission remains unchanged: to ensure that people, wherever they live, can benefit from timely access to effective health products,” said Charles Gore, MPP Executive Director. “But as our work has evolved beyond medicines alone, so too has the way we present ourselves. While our name reflects our origins, MPP today works across a broader range of health products and technologies, combining public health-oriented voluntary licensing with increasing support for technology transfer. Our refreshed visual identity better reflects this reality.”
The new logo draws inspiration from medicines such as tablets and capsules, grounding MPP’s visual identity in tangible care and access to treatment. Rounded shapes reflect humanity and inclusion, while the repetition of elements conveys progress and expansion, mirroring MPP’s evolving role in expanding access to health products. The gradient, carried over from MPP’s previous visual identity, has been intentionally retained as a link to the organisation’s history and continuity, symbolising MPP’s enduring role as a facilitator that brings together diverse partners to expand access to innovative products and other health technologies.
The refreshed identity accompanies the development of MPP’s new Strategy for 2026-2030, which sets out the organisation’s strategic priorities, objectives and targets for the coming years. While the strategy will be formally launched in May 2026, MPP will host a preview webinar on 26 March 2026 to share its key elements and strategic direction with partners and stakeholders.
The new branding will be rolled out progressively across MPP’s communications platforms and materials.
Download the brandbook and the logo pack
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.